Adage Capital Partners
BOLD

Adage Capital Partners’s Audentes Therapeutics, Inc BOLD Stock Holding History

Adage Capital Partners’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-225,000
Closed -$8.52M – 778
2019
Q2 		$8.52M Buy
225,000
+58,000
+35% +$2.23M 0.02% 550
2019
Q1 		$6.52M Buy
+167,000
New +$4.79M 0.02% 584
2018
Q2 		– Sell
-225,000
Closed -$6.76M – 815
2018
Q1 		$6.76M Sell
225,000
-525,000
-70% -$17.8M 0.02% 612
2017
Q4 		$23.4M Sell
750,000
-1,150,000
-61% -$31.6M 0.05% 366
2017
Q3 		$53.2M Hold
1,900,000
– – 0.13% 212
2017
Q2 		$36.3M Buy
1,900,000
+1,287,489
+210% +$20.6M 0.09% 295
2017
Q1 		$10.4M Buy
612,511
+170,511
+39% +$2.76M 0.03% 529
2016
Q4 		$8.07M Hold
442,000
– – 0.02% 556
2016
Q3 		$7.87M Buy
+442,000
New +$6.71M 0.02% 558

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Adage Capital Partners's BOLD Position: Q3 2019 in Review

Adage Capital Partners sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2019, closing a stake of 225,000 shares — an estimated $8.52M sold.

Adage Capital Partners first reported a position in BOLD in Q3 2016 and held it in 9 quarters. The position peaked at $53.2M in Q3 2017. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

  • Adage Capital Partners reported no remaining Audentes Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Adage Capital Partners sold 225,000 Audentes Therapeutics, Inc shares in Q3 2019, an estimated $8.52M.
  • Adage Capital Partners first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 9 quarters.
  • Adage Capital Partners's Audentes Therapeutics, Inc position peaked at $53.2M in Q3 2017.
  • 149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Adage Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.